Indian Journal of Dermatology
: 2021  |  Volume : 66  |  Issue : 2  |  Page : 203--205

Clinician severity assessment grading scale on erythematotelangiectatic rosacea

Jong-Kil Seo, Eun-Jae Shin, Ki-Heon Jeong, Min Kyung Shin 
 Department of Dermatology, School of Medicine, Kyung Hee University, Seoul, Korea

Correspondence Address:
Min Kyung Shin
Department of Dermatology, School of Medicine, Kyung Hee University, Seoul

How to cite this article:
Seo JK, Shin EJ, Jeong KH, Shin MK. Clinician severity assessment grading scale on erythematotelangiectatic rosacea.Indian J Dermatol 2021;66:203-205

How to cite this URL:
Seo JK, Shin EJ, Jeong KH, Shin MK. Clinician severity assessment grading scale on erythematotelangiectatic rosacea. Indian J Dermatol [serial online] 2021 [cited 2021 Nov 27 ];66:203-205
Available from:

Full Text


Rosacea is a chronic cutaneous inflammatory disease that primarily affects the central face and is often characterized by flushing, erythema, telangiectasia, papules, and pustules.[1] Erythematotelangiectatic rosacea (ETR), a subtype of rosacea, is primarily characterized by flushing, persistent central facial erythema, and telangiectasia.[2]

Variety of scales are used to measure the severity of ETR according to its different clinical features. Despite these various measures, larger-scale studies and validated scales are needed for precise and consistent severity assessment of clinical rosacea features. In this study, we devised a new tool that reflects these factors and is limited to ETR. Our purpose was to evaluate the reliability and objectivity of new erythema and telangiectasia severity index on ETR by determining interrater and intrarater agreement.

We performed a retrospective chart review of patients who visited the Department of Dermatology at Kyung Hee Medical Center (KHMC), Seoul, Korea, from 1 February 2015 to 30 April 2016. All 80 (60 females and 20 males) patients with ETR were aged 18 years or older (the mean age was 50.93 years). The new assessment method investigated in this study consists of three scales: Clinician's Erythema Assessment (CEA), area, and telangiectasia [Figure 1]. We thus named this new tool CAT (CEA, Area, and Telangiectasia).{Figure 1}

Each six trained clinicians rated each subject twice with at least a 2-h interval between evaluation sessions. The data were analyzed using the weighted kappa statistic and intraclass correlation coefficient (ICC) to evaluate interrater and intrarater reliability. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) 20.0 (SPSS Inc., Chicago, IL, USA). Compared with previous studies,[3] our study showed higher ICC values for CEA in interrater, but the weighted kappa values were somewhat lower, and both values in intrarater reliability were higher [Table 1]. The weighted kappa statistic and ICC of CEA and area indicate a fair to good reproducibility.{Table 1}

The previously used methods for severity assessment of rosacea had practical issues. First, most of the papers using the severity assessment of rosacea did not consider the rosacea area and were limited to erythema intensity.[4] Second, because most of the papers assessed a specific sign or symptom of rosacea, there was a limit to the ability to assess its overall status. In contrast, the Investigator's Global Assessment could not completely evaluate the detailed signs and symptoms of rosacea. There has been almost no method to judge both rosacea specific signs and the overall condition.[5]

The index used in our study includes the lesion area, similar to the Eczema Area and Severity Index for atopic dermatitis. These severity score systems quantify the lesion area. And unlike the clinician global assessment, our index is superior to clinical judgment because it addresses the detailed signs of ETR.

We confirmed that the CEA is reliable, and the area index also showed high reliability. The telangiectasia scale showed lower reliability than the CEA and area scales, indicating the necessity for other evaluation approaches such as dermoscopy. CAT could provide valid ETR severity assessment and assess the efficacy of treatment.

Financial support and sponsorship

This work was supported by a grant from the Korean Research Foundation in 2017 (NRF-2017R1C1B5076162).

Conflicts of interest

There are no conflicts of interest.


1Crawford GH, Pelle MT, James WD. Rosacea, I: Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004;51:327-41; quiz 342-4.
2Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: Report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002;46:584-7.
3Tan J, Liu H, Leyden JJ, Leoni MJ. Reliability of clinician erythema assessment grading scale. J Am Acad Dermatol 2014;71:760-3.
4Gessert CE, Bamford JTM. Measuring the severity of rosacea: A review. Int J Dermatol 2003;42:444-8.
5Hopkinson D, Tuchayi SM, Alinia H, Feldman SR. Assessment of rosacea severity: A review of evaluation methods used in clinical trials. J Am Acad Dermatol 2015;73:138-43.